Chandan Kumar

Associate Research Scientist

University of Michigan
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2025

Year:

2025

Year:

2025

Purpose: Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical trial in patients with advanced biliary tract cancer (BTC). Patients and Methods: Cell viability assays of devimistat ± gemcitabine and cisplatin (GC) were performed and the effect of devimistat on mitochondrial respiration via oxygen consumption rate (OCR) was evaluated. A phase Ib/II trial was initiated in patients with untreated advanced BTC. In phase Ib, devimistat was infused over 2 hours in combination with GC on days 1 and 8 every 21 days with a primary objective to determine the recommended phase II dose (RP2D). Secondary objectives included safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: In vitro, devimistat with GC had a synergistic effect on two cell lines. Devimistat significantly decreased OCR at higher doses and in arms with divided dosing. In the phase Ib trial, 20 patients received a median of nine cycles (range, 3–19). One DLT was observed, and the RP2D of devimistat was determined to be 2,000 mg/m2 in combination with GC. Most common grade 3 toxicities included neutropenia (n = 11, 55%), anemia (n = 4, 20%), and infection (n = 3, 15%). There were no grade 4 toxicities. After a median follow-up of 15.6 months, ORR was 45% and median PFS was 10 months (95% confidence interval, 7.1–14.9). Median OS is not yet estimable. Conclusions: Devimistat in combination with GC is well tolerated and has an acceptable safety profile in patients with untreated advanced BTC.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Ute Scholl

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Tracy Ann Williams

-

GERMANY
View details

Vaibhav Sahai

University of Michigan

UNITED STATES
View details

Richard Warth

University of Regensburg

GERMANY
View details

Jiaqi Shi

Professor

University of Michigan

UNITED STATES
View details

Arathi Mohan

Clinical Assistant Professor

University of Michigan

UNITED STATES
View details

Desmaré van Rooyen

Research Investigator

University of Michigan

UNITED STATES
View details

Antonio Marcondes Lerario

University of Michigan

UNITED STATES
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Michelle Jacobs

University of Michigan Medical School

UNITED STATES
View details

Andrea T. Franson

-

UNITED STATES
View details

Jamie Mills

Clinical Assistant Professor

University of Michigan

UNITED STATES
View details

Timothy Frankel

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Bernt Popp

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Frederike Butz

Charité - Universitätsmedizin Berlin

GERMANY
View details